Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

acebo consistently across all five endpoints studied, including both of the endpoints accepted by the FDA to register drugs for mild to moderate Alzheimer's disease. And second, Dimebon was well tolerated in this study, with less than three percent incidence of the gastrointestinal side effects that sometimes limit utilization of approved cholinesterase inhibitor drugs. Based on these data, I look forward to participating in the planned Phase 3 trials of this promising drug candidate."

The study of 183 patients was conducted at multiple sites in Russia. Patients received oral Dimebon, 20 mg three times a day (60 mg/day), or placebo. The primary efficacy endpoint was the ADAS-cog and the secondary efficacy endpoints were the CIBIC-plus, the MMSE, the ADCS-ADL and the NPI. Medivation is presently completing a 12-month extension of this trial and expects to report top-line data in the second quarter of 2007. Medivation also expects to enter global Phase 3 studies of Dimebon in Alzheimer's disease in 2008 and, assuming positive data, to submit marketing applications in the U.S. and Europe in 2010 for this indication.

About Dimebon

Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases.

Abo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:10/22/2014)... BASKING RIDGE, N.J. , Oct. 22, 2014 ... (RMANJ), a world-renowned leader in the field ... more rapid approach to embryonic screening. The research ... American Society for Reproductive Medicine (ASRM) meeting in ... chromosome screening (CCS) and single gene defect (SGD) ...
(Date:10/22/2014)... -- CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that James Patrick ... been elected to the Company,s Board of Directors, effective ... , Executive Chairman of CryoLife, stated, "Since joining the Company ... leader who is well positioned to maximize CryoLife,s potential. ...
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... Feb. 22 Immtech Pharmaceuticals,Inc. (Amex: IMM ... on its new,drug discovery programs targeting Hepatitis C, ... all development programs for,pafuramidine maleate ("pafuramidine"), an investigational ... reports related to additional,events identified in a cohort ...
... at Six-Month Follow-up of 57 Patients, MINNEAPOLIS, ... ), manufacturer and marketer of state-of-the-art cardiac,surgery products, ... and an overall expansion into the stand-alone market,using ... surgical products,indicated for the treatment of cardiac arrhythmias, ...
Cached Medicine Technology:Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine 2Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine 3Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine 4ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line 2ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line 3ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line 4ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line 5
(Date:10/25/2014)... Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Diagnostics listing their product specification, capacity, Production ...
(Date:10/25/2014)... Everett, WA (PRWEB) October 25, 2014 ... their insulation has ‘gone bad’ need wonder no more. ... that homeowners should watch out for when it ... Bad insulation, according to the article released by Clean ... emphasize for homeowners that any insulation that has deteriorated, ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival ... (Alimta), after his combination drug therapy became too toxic. ... just posted on the Surviving Mesothelioma website. , ... in Japan suggests that “maintenance therapy” with pemetrexed may ... cannot tolerate higher doses of cisplatin. , “Although ...
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2
... According to a recent,study(1), more than 6.1 ... (HSA)-eligible insurance plans, a 35 percent increase since,last ... and,flexible spending accounts (FSAs) to cut costs associated ... 6,300 convenient,locations nationwide, is making it easier for ...
... LAUREL, N.J., June 18 After 25 years, 26 ... (DNA) is,on the brink of a new era. And, ... of non-members alike can read the latest news,and cutting-edge ... will be available, in its entirety, online, offering readers,more ...
... College Living Experience, NASHVILLE, Tenn., June 18 ... Martin has been appointed senior,vice president of operations ... helps students with autism and other special needs ... operations, clinical, behavioral and,curricular initiatives for the six ...
... IL, June 18 /PRNewswire-FirstCall/ - SXC Health Solutions ... TSX: SXC), a leading provider of,pharmacy benefits management ... will present at the Jefferies 2nd Annual Healthcare,Conference ... place on Tuesday,June 24, 2008 at 11:45 am ...
... of urology officials signed an agreement Tuesday to ... test an experimental therapy for advanced prostate cancer ... , CureVac which specializes in the therapeutic ... genetic information from nuclear DNA to cellular protein ...
... ANDOVER, Mass., June 18 Sentillion announced ... organizations have selected,Sentillion,s proVision solution to create centralized ... manual user account,management, including:, -- Ardent ... System (Birmingham, AL) -- Hawaii Pacific Health ...
Cached Medicine News:Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 2Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 3Health News:CVS/pharmacy Makes It Easier for Consumers to Save Money and Track Spending with Health Savings and Flexible Spending Accounts 4Health News:Dermatology Nurses' Association Teams with International Publisher to Launch its Own Journal 2Health News:Dermatology Nurses' Association Teams with International Publisher to Launch its Own Journal 3Health News:Educational Services of America Names a New Senior VP of Operations 2Health News:UF scientists to work with German firm in prostate cancer treatment research 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 3
... The Primus 96 Thermal Cyclers provide comprehensive ... They are ideal instruments for the optimization ... as for low to medium throughput PCR ... the 96 well block allows a choice ...
... With RoboCycler Gradient 40 or 96 temperature ... generate a linear temperature range of up to ... block, respectively with a temperature difference of up ... This means you can test up to 12 ...
... precision, more user-friendliness and absolute reliability united ... definition of the Mastercycler ep system. In ... has been developing dynamically. The same applies ... To keep pace with these technological ...
... has a compact design for personal use, yet is ... handle up to 32 samples simultaneously. It contains a ... need to add mineral oil to prevent evaporation of ... stored, and up to 15 steps can be freely ...
Medicine Products: